US EditionExperimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial
4 Articles
4 Articles
Sharpened CAR-T cells are considered to be one of the most promising innovations in cancer medicine. So far, however, this has mainly been the case for blood cancer.
Gastric Cancer: Promising Therapy Shows 40% Survival Rate in Advanced Stages
Immunotherapy by CAR-T cells, so far reserved for blood cancers, is now established as a credible strategy in the face of solid tumors, long considered inaccessible to this type of treatment. Advanced gastric cancer, particularly aggressive, remains one of the major causes of oncological mortality, with few therapeutic options once standard treatments are exhausted. Carsgen, conducted the very first randomized controlled trial evaluating CAR-T t…
Car-T cell immunotherapy, previously reserved for blood cancers, is now a credible strategy for solid tumours, long considered to be inaccessible to this type of treatment. Advanced gastric cancer, particularly aggressive, remains one of the major causes of oncological mortality, with few therapeutic options once standard treatments have been exhausted. In this context, a team at Peking University Cancer Hospital, in collaboration with Chinese b…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
